The 20th Annual Transfusion Medicine Educational Web Conference Symposium hosted by Canadian Blood Services and the Ontario Regional Blood Coordinating Network (ORBCoN) is taking place virtually on May 1, 2025.This symposium is designed to enhance the transfusion skills of healthcare professionals

This eCast will provide essential insights into addressing unconscious bias and developing inclusive strategies for diverse community engagement. Attendees will gain a comprehensive understanding of how hidden biases can shape decision-making, influence team dynamics, and affect interactions with

For more than 60 years, cell therapies have focused on autologous treatments derived from a patient’s own cells, including the current FDA-approved cell-based therapies. FDA regulations and accreditation standards in cell therapy were developed predominantly around the collection, manufacture, and

This program will provide an overview of warm autoimmune hemolytic anemia (WAIHA), including clinical laboratory presentation and clinical management. The speaker will conclude with case-based reviews. Presented by Hind Kurbaj, MS, SBB Director/Moderator Houston, TX Linda Song, MD, MSPH Speaker

A subset of patients with hematologic malignancies develop immune-based refractoriness to platelet transfusions. Diagnosing and dealing with platelet refractoriness is critical for a patient’s survival. This program will explore the basis of refractoriness, standard strategies used, and alternative

This program will introduce the 12th Edition of AABB Standards for Cellular Therapy Services. The speakers will summarize the new and revised requirements incorporated into the 12th Edition of Standards. In addition, the rationale for the changes will be presented and reviewed. Presented by

Clinically insignificant high incidence antibodies, also known as high titer low avidity (HTLA) reacting antibodies, can be confusing and cause difficulty in antibody identification. This program will provide a lecture-based overview of the blood group antigens associated with these antibodies and

For many patients with sickle cell disease (SCD), hematopoietic stem cell transplantation is unavailable due to lack of a matched donor. Gene therapy using autologous gene-edited stem cells has emerged as an option for these patients. Two gene therapy regimens have been approved by the FDA and

Clinical medicine is rife with ethical issues. Even though the laboratory is largely removed from direct patient-facing care, ethical issues commonly arise. Having a framework for identifying, analyzing, and resolving ethical dilemmas is key to ensuring excellent patient care and a safe environment

Cellular therapy products are cryopreserved and stored in liquid nitrogen freezers for subsequent transplantation into recipients. Storage duration is variable but is typically a few weeks to a few years. Unused products may continue to be stored for many decades after the recipient has been